Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology
BackgroundAndrogen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly improved patient survival, the suppression of testoste...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1345322/full |
| _version_ | 1797338419168280576 |
|---|---|
| author | Darren M. C. Poon Darren M. C. Poon Guang-Ming Tan Kuen Chan Marco T. Y. Chan Tim-Wai Chan Raymond W. M. Kan Martin H. C. Lam Clarence L. H. Leung Kenneth C. W. Wong Kevin K. H. Kam Chi-Fai Ng Peter K. F. Chiu |
| author_facet | Darren M. C. Poon Darren M. C. Poon Guang-Ming Tan Kuen Chan Marco T. Y. Chan Tim-Wai Chan Raymond W. M. Kan Martin H. C. Lam Clarence L. H. Leung Kenneth C. W. Wong Kevin K. H. Kam Chi-Fai Ng Peter K. F. Chiu |
| author_sort | Darren M. C. Poon |
| collection | DOAJ |
| description | BackgroundAndrogen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly improved patient survival, the suppression of testosterone is associated with an increased risk of cardiometabolic syndrome. This highlights the urgency of multidisciplinary efforts to address the cardiometabolic risk of anticancer treatment in men with PCa.MethodsTwo professional organizations invited five urologists, five clinical oncologists, and two cardiologists to form a consensus panel. They reviewed the relevant literature obtained by searching PubMed for the publication period from April 2013 to April 2023, to address three discussion areas: (i) baseline assessment and screening for risk factors in PCa patients before the initiation of ADT and AR axis-targeted therapies; (ii) follow-up and management of cardiometabolic complications; and (iii) selection of ADT agents among high-risk patients. The panel convened four meetings to discuss and draft consensus statements using a modified Delphi method. Each drafted statement was anonymously voted on by every panelist.ResultsThe panel reached a consensus on 18 statements based on recent evidence and expert insights.ConclusionThese consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa. |
| first_indexed | 2024-03-08T09:29:57Z |
| format | Article |
| id | doaj.art-647ec4050db24cd28b254ed2c3cf2112 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-08T09:29:57Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-647ec4050db24cd28b254ed2c3cf21122024-01-31T04:39:01ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-01-011410.3389/fonc.2024.13453221345322Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-OncologyDarren M. C. Poon0Darren M. C. Poon1Guang-Ming Tan2Kuen Chan3Marco T. Y. Chan4Tim-Wai Chan5Raymond W. M. Kan6Martin H. C. Lam7Clarence L. H. Leung8Kenneth C. W. Wong9Kevin K. H. Kam10Chi-Fai Ng11Peter K. F. Chiu12Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaComprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, ChinaDivision of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong SAR, ChinaDivision of Urology, Department of Surgery, Tuen Mun Hospital, Hong Kong, Hong Kong SAR, ChinaDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR, ChinaeFLO Urology, Hong Kong, Hong Kong SAR, ChinaHong Kong Integrated Oncology Centre, Hong Kong, Hong Kong SAR, ChinaDepartment of Surgery, Kwong Wah Hospital, Hong Kong, Hong Kong SAR, China0Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDivision of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China1S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China1S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaBackgroundAndrogen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly improved patient survival, the suppression of testosterone is associated with an increased risk of cardiometabolic syndrome. This highlights the urgency of multidisciplinary efforts to address the cardiometabolic risk of anticancer treatment in men with PCa.MethodsTwo professional organizations invited five urologists, five clinical oncologists, and two cardiologists to form a consensus panel. They reviewed the relevant literature obtained by searching PubMed for the publication period from April 2013 to April 2023, to address three discussion areas: (i) baseline assessment and screening for risk factors in PCa patients before the initiation of ADT and AR axis-targeted therapies; (ii) follow-up and management of cardiometabolic complications; and (iii) selection of ADT agents among high-risk patients. The panel convened four meetings to discuss and draft consensus statements using a modified Delphi method. Each drafted statement was anonymously voted on by every panelist.ResultsThe panel reached a consensus on 18 statements based on recent evidence and expert insights.ConclusionThese consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa.https://www.frontiersin.org/articles/10.3389/fonc.2024.1345322/fullabirateroneapalutamidedarolutamidedegarelixenzalutamidegonadotropin-releasing hormone |
| spellingShingle | Darren M. C. Poon Darren M. C. Poon Guang-Ming Tan Kuen Chan Marco T. Y. Chan Tim-Wai Chan Raymond W. M. Kan Martin H. C. Lam Clarence L. H. Leung Kenneth C. W. Wong Kevin K. H. Kam Chi-Fai Ng Peter K. F. Chiu Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology Frontiers in Oncology abiraterone apalutamide darolutamide degarelix enzalutamide gonadotropin-releasing hormone |
| title | Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology |
| title_full | Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology |
| title_fullStr | Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology |
| title_full_unstemmed | Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology |
| title_short | Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology |
| title_sort | addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis targeted therapy consensus statements from the hong kong urological association and the hong kong society of uro oncology |
| topic | abiraterone apalutamide darolutamide degarelix enzalutamide gonadotropin-releasing hormone |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1345322/full |
| work_keys_str_mv | AT darrenmcpoon addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT darrenmcpoon addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT guangmingtan addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT kuenchan addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT marcotychan addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT timwaichan addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT raymondwmkan addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT martinhclam addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT clarencelhleung addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT kennethcwwong addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT kevinkhkam addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT chifaing addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology AT peterkfchiu addressingtheriskandmanagementofcardiometaboliccomplicationsinprostatecancerpatientsonandrogendeprivationtherapyandandrogenreceptoraxistargetedtherapyconsensusstatementsfromthehongkongurologicalassociationandthehongkongsocietyofurooncology |